Skip to main content
. 2020 Jun 24;18:272–281. doi: 10.1016/j.omto.2020.06.016

Figure 1.

Figure 1

Comparison of the Anti-leukemic Efficacy and Adverse Effects of CD28- and 4-1BB-Based Chimeric Antigen Receptor-T (CAR-T) Cells in Tumor-Bearing Mice

(A) Bioluminescence images of tumor-bearing mice treated with saline, CD28 CAR-T cells, or 4-1BB CAR-T cells at a dose of 1 × 107 cells/mouse. (B) Cytokine expression level in the sera of mice after CAR-T cell infusion at a dose of 1 × 107 cells/mouse. (C) Bioluminescence images of tumor-bearing mice treated with saline, CD28 CAR-T cells, or 4-1BB CAR-T cells at a dose of 1 × 106 cells/mouse. (D) The survival curve of mice treated with a lower dose of CAR-T cells. (E) Serum cytokine levels after CAR-T cell injection at low dose. ∗∗p < 0.01, and the error bars represent the standard derivation.